113 related articles for article (PubMed ID: 19639221)
1. Bis(maltolato)-oxovanadium (IV)-induced phosphorylation of PKB, GSK-3 and FOXO1 contributes to its glucoregulatory responses (review).
Vardatsikos G; Mehdi MZ; Srivastava AK
Int J Mol Med; 2009 Sep; 24(3):303-9. PubMed ID: 19639221
[TBL] [Abstract][Full Text] [Related]
2. Involvement of insulin-like growth factor type 1 receptor and protein kinase Cdelta in bis(maltolato)oxovanadium(IV)-induced phosphorylation of protein kinase B in HepG2 cells.
Mehdi MZ; Vardatsikos G; Pandey SK; Srivastava AK
Biochemistry; 2006 Sep; 45(38):11605-15. PubMed ID: 16981720
[TBL] [Abstract][Full Text] [Related]
3. Organo-vanadium compounds are potent activators of the protein kinase B signaling pathway and protein tyrosine phosphorylation: mechanism of insulinomimesis.
Mehdi MZ; Srivastava AK
Arch Biochem Biophys; 2005 Aug; 440(2):158-64. PubMed ID: 16055077
[TBL] [Abstract][Full Text] [Related]
4. In vivo effects of insulin and bis(maltolato)oxovanadium (IV) on PKB activity in the skeletal muscle and liver of diabetic rats.
Marzban L; Bhanot S; McNeill JH
Mol Cell Biochem; 2001 Jul; 223(1-2):147-57. PubMed ID: 11681716
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the glucose-lowering properties of vanadyl sulfate and bis(maltolato)oxovanadium(IV) following acute and chronic administration.
Yuen VG; Orvig C; McNeill JH
Can J Physiol Pharmacol; 1995 Jan; 73(1):55-64. PubMed ID: 7600453
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanism of bis(maltolato)oxovanadium(IV)-induced insulin signaling in 3T3-L1 and IM9 cells: impact of dexamethasone.
Bose S; Farah MA; Jung HC; Lee JH; Kim Y
J Mol Endocrinol; 2007 Jun; 38(6):627-49. PubMed ID: 17556533
[TBL] [Abstract][Full Text] [Related]
7. Glucose-lowering effects of a new organic vanadium complex, bis(maltolato)oxovanadium(IV).
Yuen VG; Orvig C; McNeill JH
Can J Physiol Pharmacol; 1993; 71(3-4):263-9. PubMed ID: 8402390
[TBL] [Abstract][Full Text] [Related]
8. Bis(maltolato)oxovanadium(IV) (BMOV) Attenuates Apoptosis in High Glucose-Treated Cardiac Cells and Diabetic Rat Hearts by Regulating the Unfolded Protein Responses (UPRs).
Cong XQ; Piao MH; Li Y; Xie L; Liu Y
Biol Trace Elem Res; 2016 Oct; 173(2):390-8. PubMed ID: 26983714
[TBL] [Abstract][Full Text] [Related]
9. A nonspecific phosphotyrosine phosphatase inhibitor, bis(maltolato)oxovanadium(IV), improves glucose tolerance and prevents diabetes in Zucker diabetic fatty rats.
Winter CL; Lange JS; Davis MG; Gerwe GS; Downs TR; Peters KG; Kasibhatla B
Exp Biol Med (Maywood); 2005 Mar; 230(3):207-16. PubMed ID: 15734724
[TBL] [Abstract][Full Text] [Related]
10. In vivo effects of vanadium in diabetic rats are independent of changes in PI-3 kinase activity in skeletal muscle.
Mohammad A; Bhanot S; McNeill JH
Mol Cell Biochem; 2001 Jul; 223(1-2):103-8. PubMed ID: 11681710
[TBL] [Abstract][Full Text] [Related]
11. The anti-diabetic bis(maltolato)oxovanadium(IV) decreases lipid order while increasing insulin receptor localization in membrane microdomains.
Winter PW; Al-Qatati A; Wolf-Ringwall AL; Schoeberl S; Chatterjee PB; Barisas BG; Roess DA; Crans DC
Dalton Trans; 2012 Jun; 41(21):6419-30. PubMed ID: 22569684
[TBL] [Abstract][Full Text] [Related]
12. New insights into the interactions of serum proteins with bis(maltolato)oxovanadium(IV): transport and biotransformation of insulin-enhancing vanadium pharmaceuticals.
Liboiron BD; Thompson KH; Hanson GR; Lam E; Aebischer N; Orvig C
J Am Chem Soc; 2005 Apr; 127(14):5104-15. PubMed ID: 15810845
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms by which bis(maltolato)oxovanadium(IV) normalizes phosphoenolpyruvate carboxykinase and glucose-6-phosphatase expression in streptozotocin-diabetic rats in vivo.
Marzban L; Rahimian R; Brownsey RW; McNeill JH
Endocrinology; 2002 Dec; 143(12):4636-45. PubMed ID: 12446591
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of insulin sensitization by BMOV (bis maltolato oxo vanadium); unliganded vanadium (VO4) as the active component.
Peters KG; Davis MG; Howard BW; Pokross M; Rastogi V; Diven C; Greis KD; Eby-Wilkens E; Maier M; Evdokimov A; Soper S; Genbauffe F
J Inorg Biochem; 2003 Aug; 96(2-3):321-30. PubMed ID: 12888267
[TBL] [Abstract][Full Text] [Related]
15. FOXO1 and GSK-3β Are Main Targets of Insulin-Mediated Myogenesis in C2C12 Muscle Cells.
Litwiniuk A; Pijet B; Pijet-Kucicka M; Gajewska M; Pająk B; Orzechowski A
PLoS One; 2016; 11(1):e0146726. PubMed ID: 26785133
[TBL] [Abstract][Full Text] [Related]
16. Effects of bis(maltolato)oxovanadium(IV) are distinct from food restriction in STZ-diabetic rats.
Yuen VG; Orvig C; McNeill JH
Am J Physiol; 1997 Jan; 272(1 Pt 1):E30-5. PubMed ID: 9038848
[TBL] [Abstract][Full Text] [Related]
17. Effects of bis(maltolato) oxovanadium (IV) on protein serine kinases in skeletal muscle of streptozotocin-diabetic rats.
Bhanot S; Girn J; Poucheret P; McNeill JH
Mol Cell Biochem; 1999 Dec; 202(1-2):131-40. PubMed ID: 10706003
[TBL] [Abstract][Full Text] [Related]
18. Calorimetric studies of the interaction between the insulin-enhancing drug candidate bis(maltolato)oxovanadium(IV) (BMOV) and human serum apo-transferrin.
Bordbar AK; Creagh AL; Mohammadi F; Haynes CA; Orvig C
J Inorg Biochem; 2009 Apr; 103(4):643-7. PubMed ID: 19056126
[TBL] [Abstract][Full Text] [Related]
19. Action mechanism of bis(allixinato)oxovanadium(IV) as a novel potent insulin-mimetic complex: regulation of GLUT4 translocation and FoxO1 transcription factor.
Hiromura M; Nakayama A; Adachi Y; Doi M; Sakurai H
J Biol Inorg Chem; 2007 Nov; 12(8):1275-87. PubMed ID: 17805585
[TBL] [Abstract][Full Text] [Related]
20. Bis(maltolato)oxovanadium(IV) attenuates hyperinsulinemia and hypertension in spontaneously hypertensive rats.
Bhanot S; Bryer-Ash M; Cheung A; McNeill JH
Diabetes; 1994 Jul; 43(7):857-61. PubMed ID: 8013747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
